Axogen and ADMA Biologics expect low to zero impact from recent tariffs

 Axogen (NASDAQ:AXGN) and ADMA Biologics (NASDAQ:ADMA) said on Monday that they expect minimal to no impact from the tariffs announced by President Donald Trump last week that led to global market declines banking on domestic operations.

Axogen said that it anticipates minimal impact from these tariffs, as well as from any retaliatory actions taken by other countries, on its current financials and underlying business model.

"The vast majority of the company's sales are domestic, as is the manufacturing of its products. The costs associated with imported materials needed for its operations is minimal," AXGN added.

“The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The company’s vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution," ADMA Biologics said in a statement.

While President Trump detailed new tariffs on U.S. imports, pharma and biotech companies were excluded from them, according to a White House fact sheet.

https://www.msn.com/en-us/money/companies/axogen-and-adma-biologics-expect-low-to-zero-impact-from-recent-tariffs/ar-AA1Cst4L?ocid=finance-verthp-feeds